Aptinyx Appears To Be Moving On From Pain With Fibromyalgia Miss

 
• By Joseph Haas

Lead candidate NYX-2925 has failed a pair of Phase IIb studies in diabetic peripheral neuropathy and now one in fibromyalgia, leaving Aptinyx’s likely last hopes in neuropsychiatric indications.

nerve cells, concept for neurodegenerative and neurological disease
Another setback in chronic pain leaves Aptinyx focusing on PTSD, dementia

More from Clinical Trials

More from R&D